On December 11, the "Forum on New Drug/Vaccine Development in the Field of Infectious Diseases" jointly organized by the National Medical Center for Infectious Diseases (Shanghai) (NMCID) and UnionClin, was successfully held in Shanghai. The meeting focused on discussing the collaborative needs throughout the entire process from the laboratory stage to commercialization and aiming to promote exchanges and cooperation among all parties to jointly advance the research and development of innovative drugs in the fields of anti-infection and infectious diseases. 

The golden autumn days come with gleaming sunshine and cool breezes. On October 25, 2024, UnionClin officially relocated its headquarters to the Science Gate of Zhangjiang Science City in Pudong, which means that UnionClin has taken another solid step forward on the path of continuous pursuit of excellence and efficient development.

On October 22, 2024, Shanghai UnionClin Co., Ltd. (hereinafter referred to as UnionClin) was conducting "A Phase 1b/2a Clinical Study of JJH201601 Liposome Injection for the Treatment of Patients with Advanced Pancreatic Cancer, Biliary Tract Cancer, and Hepatocellular Carcinoma" at Nanjing Tianyinshan Hospital, and the first subject was successfully enrolled and treated.

Clinical Research Associates (CRAs) and Clinical Research Coordinators (CRCs) are important forces assisting sponsors and investigators in conducting clinical studies and are frontline workers responsible for controlling and ensuring the quality of clinical studies. 

On March 15, 2024, UnionClin invited insightful and influential experts and leaders in the field of pharmaceutical innovation, together with pharmaceutical colleagues from various sectors, to gather in Gusu, and the UnionClin Suzhou Salon concluded successfully.